Jim Simons’s LENZ Therapeutics LENZ Stock Holding History

Jim Simons’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$401K	Buy	+70,628	New	+$569K	﹤0.01%	2682
2025 Q1	–	Sell	-25,366	Closed	-$732K	–	3912
2024 Q4	$732K	Sell	25,366 -23,900	-49%	-$729K	﹤0.01%	2652
2024 Q3	$1.17M	Sell	49,266 -10,900	-18%	-$242K	﹤0.01%	2345
2024 Q2	$1.04M	Buy	60,166 +13,300	+28%	+$232K	﹤0.01%	2297
2024 Q1	$1.05M	Sell	46,866 -36,156	-44%	-$752K	﹤0.01%	2460
2023 Q4	$1.52M	Buy	83,022 +45,251	+120%	+$747K	﹤0.01%	2121
2023 Q3	$656K	Buy	37,771 +2,900	+8%	+$50.4K	﹤0.01%	2581
2023 Q2	$635K	Buy	34,871 +2,271	+7%	+$45.4K	﹤0.01%	2740
2023 Q1	$559K	Sell	32,600 -14,525	-31%	-$235K	﹤0.01%	2826
2022 Q4	$1.09M	Sell	47,125 -27,442	-37%	-$636K	﹤0.01%	2481
2022 Q3	$1.66M	Sell	74,567 -37,904	-34%	-$903K	﹤0.01%	2150
2022 Q2	$2.17M	Buy	+112,471	New	+$2.51M	﹤0.01%	2129

Other funds holding LENZ

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's LENZ Position: Q2 2026 in Review

Jim Simons opened a new position in LENZ Therapeutics (LENZ) in Q2 2026: 70,628 shares worth $401K. The stake represents ﹤0.01% of the portfolio and ranks #2682 among its holdings. This is a return to the name: Jim Simons previously reported a position in LENZ as recently as Q4 2024.

Jim Simons first reported a position in LENZ in Q2 2022 and has held it in 12 quarters since. The position peaked at $2.17M in Q2 2022. 87 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Jim Simons held 70,628 shares of LENZ Therapeutics worth $401K as of Q2 2026.
LENZ Therapeutics was a new Jim Simons position in Q2 2026.
LENZ Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2682 holding.
Jim Simons first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 12 quarters since.
Jim Simons's LENZ Therapeutics position peaked at $2.17M in Q2 2022.
87 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.